China Biologic Products (NASDAQ:CBPO) Upgraded at BidaskClub

BidaskClub upgraded shares of China Biologic Products (NASDAQ:CBPO) from a strong sell rating to a sell rating in a research note released on Wednesday, December 20th.

Separately, Zacks Investment Research upgraded China Biologic Products from a sell rating to a hold rating in a report on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. China Biologic Products has a consensus rating of Hold and an average target price of $137.50.

Shares of China Biologic Products (NASDAQ CBPO) traded up $3.87 during midday trading on Wednesday, reaching $81.37. The company’s stock had a trading volume of 198,181 shares, compared to its average volume of 183,053. The company has a market cap of $2,570.00, a price-to-earnings ratio of 21.19, a PEG ratio of 0.98 and a beta of 1.79. China Biologic Products has a 1-year low of $72.21 and a 1-year high of $120.46.

Several hedge funds have recently modified their holdings of CBPO. Hillhouse Capital Management Ltd. lifted its holdings in shares of China Biologic Products by 186.8% in the 2nd quarter. Hillhouse Capital Management Ltd. now owns 753,624 shares of the biopharmaceutical company’s stock valued at $85,235,000 after buying an additional 490,874 shares during the period. Schroder Investment Management Group raised its holdings in China Biologic Products by 771.5% in the 2nd quarter. Schroder Investment Management Group now owns 544,676 shares of the biopharmaceutical company’s stock worth $60,845,000 after purchasing an additional 482,175 shares during the period. Macquarie Group Ltd. raised its holdings in China Biologic Products by 115.3% in the 2nd quarter. Macquarie Group Ltd. now owns 587,587 shares of the biopharmaceutical company’s stock worth $66,456,000 after purchasing an additional 314,700 shares during the period. Artisan Partners Limited Partnership raised its holdings in China Biologic Products by 62.9% in the 3rd quarter. Artisan Partners Limited Partnership now owns 723,859 shares of the biopharmaceutical company’s stock worth $66,790,000 after purchasing an additional 279,420 shares during the period. Finally, Comgest Global Investors S.A.S. raised its holdings in China Biologic Products by 135.0% in the 3rd quarter. Comgest Global Investors S.A.S. now owns 356,252 shares of the biopharmaceutical company’s stock worth $32,872,000 after purchasing an additional 204,649 shares during the period. 65.13% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “China Biologic Products (NASDAQ:CBPO) Upgraded at BidaskClub” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/13/china-biologic-products-cbpo-stock-rating-upgraded-by-bidaskclub.html.

About China Biologic Products

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply